

#18  
p.1



## MATERIAL SAFETY DATA SHEET

**Product Name:** Lidocaine Hydrochloride Injection, USP

### 1. CHEMICAL PRODUCT AND COMPANY INFORMATION

**Manufacturer Name And Address**  
Hospira, Inc.  
275 North Field Drive  
Lake Forest, Illinois 60045  
USA

**Note:** Hospira, formerly the Hospital Products Division of Abbott Laboratories, was created as an independent company in May 2004.

**Emergency Telephone**  
Hospira, Inc.  
CHEMTREC: 800 424-9300  
224 212-2055

**Product Name** Lidocaine Hydrochloride Injection/Topical Solution, USP

**Synonyms** None

I-282840 C-477302  
I-243244 C-428301  
I-243243 C-427902  
I-243241 C-427701  
I-243240 C-427501  
I-239936 C-427602  
I-239935 C-427601  
I-225095 C-793932  
I-209180 C-793132  
I-209179 C-793124

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

**Ingredient Name** Lidocaine Hydrochloride  
**Chemical Formula**  $C_{14}H_{23}ClN_2O$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Lidocaine Hydrochloride	0.05 - 0.5	73-78-9	AN7600000
Water	99	7732-18-5	ZC0110000

### 3. HAZARD INFORMATION

**Emergency Overview** In clinical use, this material is used to numb body tissues. Lidocaine is toxic by ingestion and besides its numbing effects, can affect the central nervous system, respiratory system, and cardiovascular system.

**Occupational Exposure Potential** Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

**Signs and Symptoms** No signs or symptoms from occupational exposure are known. Clinical data suggest the following: numbness, lightheadedness, transient deafness, drowsiness, dizziness, restlessness, breathing difficulty, anxiety, vomiting, tremor, stupor, convulsions, respiratory distress, decreased blood pressure, slow heart rate.

**Medical Conditions Aggravated by Exposure** Hypersensitivity to the material and/or similar materials. Pre-existing ailments in the following organs: eyes, central nervous system, cardiovascular system.

I-336739 C-471332  
I-243242 C-427801  
D6m I-486577 C-00074428201  
I-493977 C-471312  
I-495534 C-428201

I-467259 C-913705  
I-427980 C-206605  
I-887413 C-132303  
Dmf I-337203 C-802701  
D6m I-827202 C-080260113  
I-336859 C-490434  
I-386743 C-477601

I-336738 C-477201  
I-336721 C-428202  
I-336717 C-427001  
I-336635 C-403601  
I-300448 C-427702  
I-295485 C-428201 D6m  
I-287029 C-49084

**Product Name: Lidocaine Hydrochloride Injection, USP**

#### **4. FIRST AID MEASURES**

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

**Ingestion:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

#### **5. FIRE FIGHTING MEASURES**

**Flammability:** Non-flammable.

**Fire & Explosion Hazard:** None

**Extinguishing Media:** Use extinguishing media appropriate for primary cause of fire.

**Special Fire Fighting Procedures** No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

#### **6. ACCIDENTAL RELEASE MEASURES**

**Spill Cleanup and Disposal** Absorb with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

#### **7. HANDLING AND STORAGE**

**Handling** No special handling required.

**Storage** No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).

**Special Precautions** Protect from freezing and extreme heat.

#### **8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

##### **Exposure Guidelines**

Component	Exposure limits		
	OSHA-PEL	ACGIH-TLV	Hospira EEL
Lidocaine Hydrochloride	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: 500 mcg/m3 STEL: 5 mg/m3

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit  
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.  
EEL: Employee Exposure Limit.  
TWA: 8 hour Time Weighted Average.  
STEL: 15-minute Short Term Exposure Limit.

**Product Name: Lidocaine Hydrochloride Injection, USP**

<b>Respiratory Protection</b>	Respiratory protection is not needed during normal product use.
<b>Skin Protection</b>	If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.
<b>Eye Protection</b>	Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.
<b>Engineering Controls</b>	Engineering controls are not needed during normal product use conditions.

**9. PHYSICAL/CHEMICAL PROPERTIES**

<b>Appearance/Physical State</b>	Clear liquid
<b>Odor</b>	Not Applicable
<b>Boiling Point</b>	Approximately that of water (100 °C, 212 °F).
<b>Freezing Point</b>	Approximately that of water (0 °C, 32 °F).
<b>Vapor Pressure</b>	Not Applicable
<b>Vapor Density (Air=1)</b>	Not Applicable
<b>Evaporation Rate</b>	Not Applicable
<b>Bulk Density</b>	Not Determined
<b>Specific Gravity</b>	Approximately that of water (1.0)
<b>Solubility</b>	Aqueous solution
<b>pH</b>	3.0 – 7.0

**10. STABILITY AND REACTIVITY**

<b>Chemical Stability</b>	Stable under standard use and storage conditions.
<b>Incompatibilities</b>	Not Determined
<b>Hazardous Decomposition Products</b>	Toxic fumes of nitrogen oxides and HCl
<b>Hazardous Polymerization</b>	Not Determined.

**11. TOXICOLOGICAL INFORMATION:****Acute Toxicity – Oral:**

<b>Ingredient(s)</b>	<b>Percent</b>	<b>Test Type</b>	<b>Value</b>	<b>Units</b>	<b>Species</b>
Lidocaine Hydrochloride	100	LD50	317	mg/kg	Rats
			220		Mice

LD50 is the dosage producing 50% mortality.

Product contains between approximately 0.05 – 0.5% Lidocaine Hydrochloride.

<b>Mutagenicity</b>	Not Determined
<b>Target Organ Effects</b>	In clinical use target organ effects include central nervous system, cardiovascular system.

**Product Name: Lidocaine Hydrochloride Injection, USP**

## **12. ECOLOGICAL INFORMATION:**

**Aquatic Toxicity** Not Available

## **13. DISPOSAL CONSIDERATIONS:**

**Waste Disposal** Disposal should be performed in accordance with the federal, state or local regulatory requirements.

**Container Handling and Disposal** Dispose of container and unused contents in accordance with federal, state, and local regulations.

## **14. TRANSPORTATION INFORMATION**

**DOT** Not Regulated

**Notes:** DOT - US Department of Transportation Regulations

## **15. REGULATORY INFORMATION**

<b>TSCA Status</b>	Not Regulated
<b>CERCLA Status</b>	Not Regulated
<b>SARA Status</b>	Not Regulated
<b>RCRA Status</b>	Not Regulated
<b>PROP 65 (Calif.)</b>	Not Regulated

**Notes:** TSCA Toxic Substance Control Act  
CERCLA US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act  
SARA Superfund Amendments and Reauthorization Act  
RCRA US EPA, Resource Conservation and Recovery Act  
Prop 65, California Proposition 65

## **16. OTHER INFORMATION:**

**MSDS Coordinator** T. Straits MPH, CIH  
**Date Prepared** September 15, 2005

### **Disclaimer:**

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.